SYRE
Spyre TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
Bull case: positive pivotal data and favourable regulatory progress push adoption expectations toward the high end of analyst targets, validating a premium multiple and supporting material upside [#SERP-1].
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -0.0.
What can break
Binary clinical readout failure or mixed efficacy
Momentum
96
Value
41
Sentiment
5
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $54.29 · Bull $73.50 · Bear $40.00
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-02-27 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $103.93
Why
Momentum96 · Δ7d -0.0
Value41 · Δ7d +0.0
Sentiment5 · Δ7d -2.7
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
96
26% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-1.1
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
5
34% active weight
Current posture
7d trendSoftening
Δ7d
-2.7
Δ21d
-9.2
Why this grade
Composite grade D. Momentum 95.7 / Value 41.1 / Sentiment 4.8
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$8.45B
Beta
3.17
Shares Out
86.84M
P/E (TTM) · Derived
-49.3
P/S (TTM)
-
P/FCF (TTM) · Derived
-35.53
Rev YoY
-100.0%
EPS YoY
+46.7%
Gross Margin
+39.5%
Op Margin
-
Net Debt
-$756.53M
Current Ratio
8.97
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology